Combination of Sulindac and Metformin as a Therapeutic Target in Lung Cancer

Sulindac is an FDA approved, non-steroidal anti-inflammatory drug that exhibits anti-cancer properties. Metformin is and FDA approved, anti-diabetic drug that also has documented anti-cancer properties. The goal of this project was to explore if a dual-combination of sulindac and metformin in the presence of a chemical oxidizing agent is more effective in killing lung cancer cells while not inducing cell death in normal lung cells. Our data shows that a triple-drug combination of sulindac, metformin, and tert-butyl hydroperoxide induce significant cell death in lung cancer cells but did not induce significant cell death in normal lung cells.